Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP ...

Drug-induced bilateral 2° ACG is an entity that can disarm the treating physician who is not aware of the entire list of drugs that may be responsible for this condition. This systematic review ...

Glaucoma is often called the “silent thief of sight” because it can damage vision without warning signs. It harms the optic ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

in the United States announced the launch of Travoprost, an ocular solution used to treat glaucoma ... equivalent to the reference listed medication, Travatan Z ophthalmic solution USP, 0.004% ...

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Image source: Official website The Travoprost ophthalmic solution ( 0.004 per cent ionic buffered solution) is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z ...

Researchers at Binghamton University are exploring several new glaucoma treatments that would ... Engineering shared their findings for drug-carrying liposomes that could be activated in the ...

Global Glaucoma Therapeutics Market Poised for Growth; Set to Reach US$7.2 Billion by 2030 Glaucoma Therapeutics Market ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...